ACR-P-D vs ABOS
Comparison between ACRES Commercial Realty Corp (ACR-P-D, Company) and Acumen Pharmaceuticals Inc (ABOS, Company).
5-Year PerformanceACR-P-D has outperformed ABOS, delivering a return of +6.4% compared to -33.8%
ACR-P-D vs ABOS - Performance Comparison
Key Characteristics
Financial metrics and valuation ratios
ACR-P-D vs ABOS - Historical Returns
Returns include dividend reinvestment.
ACR-P-D vs ABOS - Annual Returns (2021 - 2026)
Returns include dividend reinvestment.
| Year | ACR-P-D | ABOS |
|---|---|---|
| 2026 | +4.34% | +7.43% |
| 2025 | +7.57% | +14.05% |
| 2024 | +8.70% | -59.34% |
| 2023 | +33.24% | -27.00% |
| 2022 | -21.82% | -19.76% |
| 2021 | +6.24% | -66.37% |
ACR-P-D vs ABOS Drawdown Comparison
The maximum drawdown for ACR-P-D was -25.76%, occurring on Jul 21, 2022. Recovery took 536 trading sessions.
The maximum drawdown for ABOS was -95.56%, occurring on Apr 17, 2025. This drawdown has not yet recovered.
The current ACR-P-D drawdown is -1.07%. The current ABOS drawdown is -89.30%.
| Rank | ACR-P-D | ABOS |
|---|---|---|
| #1 | -25.76% Nov 4, 2021 - Dec 22, 2023 | -95.56% Jul 2, 2021 - Apr 17, 2025 |
| #2 | -17.84% Aug 6, 2024 - Jul 1, 2025 | N/A |
| #3 | -10.47% Jan 25, 2024 - Jul 22, 2024 | N/A |
| #4 | -3.93% Oct 1, 2025 - Nov 4, 2025 | N/A |
| #5 | -3.23% Jun 15, 2026 - Jun 30, 2026 | N/A |
| #6 | -2.77% Jul 25, 2024 - Jul 31, 2024 | N/A |
| #7 | -2.48% Feb 17, 2026 - Apr 17, 2026 | N/A |
| #8 | -2.43% Dec 29, 2023 - Jan 22, 2024 | N/A |
| #9 | -2.33% Jul 22, 2025 - Aug 26, 2025 | N/A |
| #10 | -1.74% Oct 14, 2021 - Nov 1, 2021 | N/A |
| #11 | -1.73% May 20, 2026 - May 27, 2026 | N/A |
| #12 | -1.72% Sep 30, 2021 - Oct 13, 2021 | N/A |
| #13 | -1.71% Sep 13, 2021 - Sep 28, 2021 | N/A |
| #14 | -1.33% Sep 18, 2025 - Oct 1, 2025 | N/A |
| #15 | -1.30% Jul 14, 2025 - Jul 16, 2025 | N/A |
Correlation
Correlation between ACR-P-D and ABOS is -0.47 which considered as a weak negative correlation - the stocks show a slight tendency to move in opposite directions.
Select Stocks to Compare
More Comparisons
Compare with similar stocks